MedTrace Logo

Real-word Study of the de NOVO Extended-release tacrolimuS in Kidney Transplantation Using an ARTificial Intelligence

NCT06960824 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 165

Last updated 2025-05-07

No results posted yet for this study

Summary

The purpose of this study is to assess the clinical efficacy of the LCPT En-varsus \[Life-Cycle Pharma Tacrolimus\] initiated in de novo (Day 0 of transplantation) using the Biopsy Proven Acute Re-jection and iBox (full and abbreviated algo-rithms).

Conditions

  • Chronic Renal Disease

Interventions

DRUG

Life-Cycle Pharma Tacrolimus

Patients receiving LCPT Envarsus® \[Life-Cycle Pharma Tacrolimus\] within 24 hours of kidney transplantation in a once-daily formulation at the discretion of the investiga-tor and in compliance with the summary of product characteristics (SmPC).

PROCEDURE

Kidney transplantation

Kidney transplant patients using the iBox prognostic system (risk prediction system for kidney transplants)

Sponsors & Collaborators

  • Chiesi SAS

    lead INDUSTRY

Principal Investigators

  • Philippe GATAULT, MD · CHRU TOURS

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-31
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06960824 on ClinicalTrials.gov